29928659|t|Liquid biopsy: a new source of candidate biomarkers in amyotrophic lateral sclerosis.
29928659|a|Noninvasive tests to diagnose and monitor the progression of neurodegenerative disorders have been a challenge for decades. The aim of this study was to explore the feasibility of applying liquid biopsy procedures to patients with a neurodegenerative disease such as amyotrophic lateral sclerosis (ALS). We isolated plasma cell-free DNA (cfDNA) in 20 ALS patients and 20 controls and used cfDNA to identify a novel differentially methylated mark in RHBDF2 gene in ALS patients compared to controls. Our findings support the notion that liquid biopsy may be applied to living patients as a source of potential epigenetic biomarkers for neurodegenerative disorders.
29928659	55	84	amyotrophic lateral sclerosis	Disease	MESH:D000690
29928659	147	174	neurodegenerative disorders	Disease	MESH:D019636
29928659	303	311	patients	Species	9606
29928659	319	344	neurodegenerative disease	Disease	MESH:D019636
29928659	353	382	amyotrophic lateral sclerosis	Disease	MESH:D000690
29928659	384	387	ALS	Disease	MESH:D000690
29928659	437	440	ALS	Disease	MESH:D000690
29928659	441	449	patients	Species	9606
29928659	535	541	RHBDF2	Gene	79651
29928659	550	553	ALS	Disease	MESH:D000690
29928659	554	562	patients	Species	9606
29928659	661	669	patients	Species	9606
29928659	721	748	neurodegenerative disorders	Disease	MESH:D019636
29928659	Association	MESH:D000690	79651

